this is a picture area with related links and other items that
will work for each section |
|
What is hypotrichosis of the eyelashes?
Hypotrichosis is another name for having inadequate or
not enough eyelashes.
What is LATISSE™ solution?
LATISSE™ solution is a prescription treatment for hypotrichosis used to grow eyelashes, making them
longer, thicker and darker.
Who should NOT take LATISSE™?
Do not use
LATISSE™ solution if you are allergic to one
of its ingredients.
Are there any special warnings associated with LATISSE™
use?
LATISSE™ solution is intended for use on the skin of the
upper eyelid margins at the base of the eyelashes. Refer
to Illustration 2. DO NOT APPLY to the lower eyelid. If
you are using LUMIGAN® or other products in the same
class for elevated intraocular pressure (IOP), or if you
have a history of abnormal IOP, you should only use
LATISSE™ under the close supervision of your physician.
LATISSE™ use may cause darkening of the eyelid skin
which may be reversible. LATISSE™ use may also cause
increased brown pigmentation of the colored part of the
eye which is likely to be permanent.
It is possible for hair growth to occur in other areas
of your skin that
LATISSE™ frequently touches. Any
excess solution outside the upper eyelid margin should
be blotted with a tissue or other absorbent material to
reduce the chance of this from happening. It is also
possible for a difference in eyelash length, thickness,
fullness, pigmentation, number of eyelash hairs, and/or
direction of eyelash growth to occur between eyes. These
differences, should they occur, will usually go away if
you stop using
LATISSE™.
Who should I tell that I am using LATISSE™?
You should tell your physician you are using
LATISSE™
especially if you have a history of eye pressure
problems.
You should also tell anyone conducting an eye pressure
screening that you are using LATISSE™.
What should I do if I get
LATISSE™ in my eye?
LATISSE™ solution is an ophthalmic drug product.
LATISSE™ is not expected to cause harm if it gets into
the eye proper. Do not attempt to rinse your eye in this
situation.
What are the possible side effects of LATISSE™?
The most common side effects after using
LATISSE™
solution are an itching sensation in the eyes and/or eye
redness. This was reported in approximately 4% of
patients.
LATISSE™ solution may cause other less common
side effects which typically occur on the skin close to
where LATISSE™ is applied, or in the eyes. These include
skin darkening, eye irritation, dryness of the eyes, and
redness of the eyelids.
If you develop a new ocular condition (e.g., trauma or
infection), experience a sudden decrease in visual
acuity, have ocular surgery, or develop any ocular
reactions, particularly conjunctivitis and eyelid
reactions, you should immediately seek your physician’s
advice concerning the continued use of
LATISSE™
solution.
What happens if I stop using LATISSE™?
If you stop using
LATISSE™, your eyelashes are expected
to return to their previous appearance over several
weeks to months.
Any eyelid skin darkening is expected to reverse after
several weeks to months.
Any darkening of the colored part of the eye known as
the iris is NOT expected to reverse and is likely
permanent.
How do I use LATISSE™?
LATISSE™ solution is packaged as a 3 mL bottle of
solution with 60 accompanying sterile, disposable
applicators. The recommended dosage is one application
nightly to the skin of the upper eyelid margin at the
base of the eyelashes only.
Once nightly, start by ensuring your face is clean,
makeup and contact lenses are removed. Remove an
applicator from its tray. Then, holding the sterile
applicator horizontally, place one drop of
LATISSE™ on
the area of the applicator closest to the tip but not on
the tip (see Illustration 1). Then immediately draw the
applicator carefully across the skin of the upper eyelid
margin at the base of the eyelashes (where the eyelashes
meet the skin) going from the inner part of your lash
line to the outer part (see Illustration 2). Blot any
excess solution beyond the eyelid margin. Dispose of the
applicator after one use.
Repeat for the opposite upper eyelid margin using a new
sterile applicator. This helps minimize any potential
for contamination from one eyelid to another.
DO NOT APPLY in your eye or to the lower lid. ONLY use
the sterile applicators supplied with
LATISSE™ to apply
the product. If you miss a dose, don’t try to “catch
up.” Just apply
LATISSE™ solution the next evening.
Fifty percent of patients treated with
LATISSE™ in a
clinical study saw significant improvement by 2 months
after starting treatment.
If any LATISSE™ solution gets into the eye proper, it is
not expected to cause harm. The eye should not be
rinsed.
Don’t allow the tip of the bottle or applicator to
contact surrounding structures, fingers, or any other
unintended surface in order to avoid contamination by
common bacteria known to cause infections.
Contact lenses should be removed prior to application of
LATISSE™ and may be reinserted 15 minutes following its
administration.
Use of LATISSE™ more than once a day will not increase
the growth of eyelashes more than use once a day.
Store LATISSE™ solution at 36o to 77oF (2o to 25oC).
General Information about LATISSE™.
Prescription treatments are sometimes prescribed for
conditions that are not mentioned in patient information
leaflets. Do not use LATISSE™ solution for a condition
for which it was not prescribed. Do not give LATISSE™ to
other people. It may not be appropriate for them to use.
This leaflet summarizes the most important information
about LATISSE™ solution. If you would like more
information, talk with your physician. You can also call Allergan’s product information department at
1-800-433-8871.
What are the ingredients in LATISSE™?
Active ingredient: bimatoprost
Inactive ingredients: benzalkonium chloride; sodium
chloride; sodium phosphate, dibasic; citric acid; and
purified water. Sodium hydroxide and/or hydrochloric
acid may be added to adjust pH. The pH during its shelf
life ranges from 6.8 - 7.8.
© 2009 Allergan, Inc., Irvine, CA 92612. ™ and ® marks
owned by Allergan, Inc., U.S. Patents 6,403,649;
7,351,404; and 7,388,029 |
|
